Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle

Alessandra Tessitore, Armida Faella, Thomas O'Malley, Gabriella Cotugno, Monica Doria, Tetsuo Kunieda, Giuseppe Matarese, Mark Haskins, Alberto Auricchio

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Mucopolysaccharidosis VI (MPS VI) is caused by deficient activity of arylsulfatase B (ARSB), resulting in intralysosomal storage of dermatan sulfate (DS) and multisystem disease without central nervous system involvement. After gene transfer, muscle or liver can theoretically be converted into factories for systemic ARSB secretion, leading to uptake by non-transduced cells. We have injected newborn MPS VI rats and cats with adeno-associated viral (AAV) vectors expressing ARSB under the control of liver-specific, muscle-specific, or universally active promoters. After systemic or intramuscular (IM) administration of AAV, therapeutic levels of circulating ARSB are achieved, resulting in skeletal improvements and significant decrease in glycosaminoglycan (GAG) storage, inflammation and apoptosis (despite a neutralizing immune response to ARSB in MPS VI rats). In addition, we have observed wide-spread dissemination of vector after IM AAV administration. This results in secretion of therapeutic levels of ARSB when the universally active cytomegalovirus (CMV) but not the muscle-specific muscle creatine kinase (MCK) promoter is used, suggesting that transduction of extramuscular sites rather than enzyme secretion from muscle occurs after muscle ARSB gene transfer. We conclude that AAV-mediated expression of ARSB from liver represents a feasible therapeutic strategy for MPS VI, potentially avoiding multiple infusions of costly recombinant enzyme associated with enzyme replacement therapy.

Original languageEnglish
Pages (from-to)30-37
Number of pages8
JournalMolecular Therapy
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Mucopolysaccharidosis VI
N-Acetylgalactosamine-4-Sulfatase
Muscles
Liver
Genes
MM Form Creatine Kinase
Enzyme Replacement Therapy
Dermatan Sulfate
Central Nervous System Diseases
Enzymes
Glycosaminoglycans
Cytomegalovirus
Cats
Therapeutics
Apoptosis
Inflammation

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. / Tessitore, Alessandra; Faella, Armida; O'Malley, Thomas; Cotugno, Gabriella; Doria, Monica; Kunieda, Tetsuo; Matarese, Giuseppe; Haskins, Mark; Auricchio, Alberto.

In: Molecular Therapy, Vol. 16, No. 1, 01.2008, p. 30-37.

Research output: Contribution to journalArticle

Tessitore, A, Faella, A, O'Malley, T, Cotugno, G, Doria, M, Kunieda, T, Matarese, G, Haskins, M & Auricchio, A 2008, 'Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle', Molecular Therapy, vol. 16, no. 1, pp. 30-37. https://doi.org/10.1038/sj.mt.6300325
Tessitore, Alessandra ; Faella, Armida ; O'Malley, Thomas ; Cotugno, Gabriella ; Doria, Monica ; Kunieda, Tetsuo ; Matarese, Giuseppe ; Haskins, Mark ; Auricchio, Alberto. / Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. In: Molecular Therapy. 2008 ; Vol. 16, No. 1. pp. 30-37.
@article{58edf1d932ab41eb95104c4139583e68,
title = "Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle",
abstract = "Mucopolysaccharidosis VI (MPS VI) is caused by deficient activity of arylsulfatase B (ARSB), resulting in intralysosomal storage of dermatan sulfate (DS) and multisystem disease without central nervous system involvement. After gene transfer, muscle or liver can theoretically be converted into factories for systemic ARSB secretion, leading to uptake by non-transduced cells. We have injected newborn MPS VI rats and cats with adeno-associated viral (AAV) vectors expressing ARSB under the control of liver-specific, muscle-specific, or universally active promoters. After systemic or intramuscular (IM) administration of AAV, therapeutic levels of circulating ARSB are achieved, resulting in skeletal improvements and significant decrease in glycosaminoglycan (GAG) storage, inflammation and apoptosis (despite a neutralizing immune response to ARSB in MPS VI rats). In addition, we have observed wide-spread dissemination of vector after IM AAV administration. This results in secretion of therapeutic levels of ARSB when the universally active cytomegalovirus (CMV) but not the muscle-specific muscle creatine kinase (MCK) promoter is used, suggesting that transduction of extramuscular sites rather than enzyme secretion from muscle occurs after muscle ARSB gene transfer. We conclude that AAV-mediated expression of ARSB from liver represents a feasible therapeutic strategy for MPS VI, potentially avoiding multiple infusions of costly recombinant enzyme associated with enzyme replacement therapy.",
author = "Alessandra Tessitore and Armida Faella and Thomas O'Malley and Gabriella Cotugno and Monica Doria and Tetsuo Kunieda and Giuseppe Matarese and Mark Haskins and Alberto Auricchio",
year = "2008",
month = "1",
doi = "10.1038/sj.mt.6300325",
language = "English",
volume = "16",
pages = "30--37",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle

AU - Tessitore, Alessandra

AU - Faella, Armida

AU - O'Malley, Thomas

AU - Cotugno, Gabriella

AU - Doria, Monica

AU - Kunieda, Tetsuo

AU - Matarese, Giuseppe

AU - Haskins, Mark

AU - Auricchio, Alberto

PY - 2008/1

Y1 - 2008/1

N2 - Mucopolysaccharidosis VI (MPS VI) is caused by deficient activity of arylsulfatase B (ARSB), resulting in intralysosomal storage of dermatan sulfate (DS) and multisystem disease without central nervous system involvement. After gene transfer, muscle or liver can theoretically be converted into factories for systemic ARSB secretion, leading to uptake by non-transduced cells. We have injected newborn MPS VI rats and cats with adeno-associated viral (AAV) vectors expressing ARSB under the control of liver-specific, muscle-specific, or universally active promoters. After systemic or intramuscular (IM) administration of AAV, therapeutic levels of circulating ARSB are achieved, resulting in skeletal improvements and significant decrease in glycosaminoglycan (GAG) storage, inflammation and apoptosis (despite a neutralizing immune response to ARSB in MPS VI rats). In addition, we have observed wide-spread dissemination of vector after IM AAV administration. This results in secretion of therapeutic levels of ARSB when the universally active cytomegalovirus (CMV) but not the muscle-specific muscle creatine kinase (MCK) promoter is used, suggesting that transduction of extramuscular sites rather than enzyme secretion from muscle occurs after muscle ARSB gene transfer. We conclude that AAV-mediated expression of ARSB from liver represents a feasible therapeutic strategy for MPS VI, potentially avoiding multiple infusions of costly recombinant enzyme associated with enzyme replacement therapy.

AB - Mucopolysaccharidosis VI (MPS VI) is caused by deficient activity of arylsulfatase B (ARSB), resulting in intralysosomal storage of dermatan sulfate (DS) and multisystem disease without central nervous system involvement. After gene transfer, muscle or liver can theoretically be converted into factories for systemic ARSB secretion, leading to uptake by non-transduced cells. We have injected newborn MPS VI rats and cats with adeno-associated viral (AAV) vectors expressing ARSB under the control of liver-specific, muscle-specific, or universally active promoters. After systemic or intramuscular (IM) administration of AAV, therapeutic levels of circulating ARSB are achieved, resulting in skeletal improvements and significant decrease in glycosaminoglycan (GAG) storage, inflammation and apoptosis (despite a neutralizing immune response to ARSB in MPS VI rats). In addition, we have observed wide-spread dissemination of vector after IM AAV administration. This results in secretion of therapeutic levels of ARSB when the universally active cytomegalovirus (CMV) but not the muscle-specific muscle creatine kinase (MCK) promoter is used, suggesting that transduction of extramuscular sites rather than enzyme secretion from muscle occurs after muscle ARSB gene transfer. We conclude that AAV-mediated expression of ARSB from liver represents a feasible therapeutic strategy for MPS VI, potentially avoiding multiple infusions of costly recombinant enzyme associated with enzyme replacement therapy.

UR - http://www.scopus.com/inward/record.url?scp=37549000936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549000936&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300325

DO - 10.1038/sj.mt.6300325

M3 - Article

C2 - 17955027

AN - SCOPUS:37549000936

VL - 16

SP - 30

EP - 37

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -